Obscure One said...
Thanks Old Hat for telling us about Advocacy for Patients with Chronic Illness, I think it's a great idea to contact them. I am astonished to discover my insurance company, Humana (medicare drug plan) is not covering delzicol. I had read that Warner-Chilcott was not going to replace asacol with delzicol till they had all the major insurance plans on board for coverage. How do they expect to make as much money if a major company like Humana isn't on board yet? That also *may* give people 'damages' to sue on, as would delzicol causing some people to flare.
The FDA only approved Delzicol in February, so I can't imagine how they would have expected to have all major insurance companies lined up.
While the FDA approval process does explain why they waited so long after the FDA's initial recommendation against the Asacol lining to do anything about
it, it also lays bare their audacious lie about
the FDA recommendation being the reason for discontinuing it now.
Always interesting to see a stock analyst applauding a company's greed:
"The United States Food and Drug Administration (FDA) approved Warner's new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The product will be marketed as Delzicol, which would be commercially launched in March 2013.
"The launch would offset the generic threat to Asacol, which would lose market exclusivity in July 2013. Delzicol is considered to be a follow-on product of the company's core product Asacol, which would no longer be sold once Delzicol hits the market. Asacol had generated $743 million in sales in 2011.
"Further, the company does not plan to price Delzicol at a premium to Asacol, which should allow for a more rapid ramp in formulary coverage.
"Notably, generic competition for the company's mesalamine based Ulcerative Colitis (UC) franchise (Asacol, Asacol HD and Delzicol) remains highly unlikely over the next few years, given the challenging pathway to approval.
"'While we were somewhat disappointed to learn that Delzicol will not enjoy 3 years of new product exclusivity, it is a new formulation (capsule vs. tablet) which leaves the opportunity for the company to secure additional patents to protect the franchise,' RBC Capital Markets analyst Shibani Malhotra wrote in a note to clients."
I took generic mesalamine for years in Canada before moving the U.S. and never had any issues. Frustrated to be beholden to these crooks again.
Post Edited (jfk3253) : 4/20/2013 11:00:15 PM (GMT-6)